The reform of the European Union’s pharmaceutical legislation, known as the ‘pharmaceutical package’, represents the first comprehensive overhaul since 2004. It consists of a new regulation and a new directive, intended to replace Directive 2001/83/EC and Regulation (EC) No 726/2004. Following the political agreement between the Council and the Parliament on 11 December 2025 and the publication of the compromise texts in March 2026, the process has entered the formal adoption phase; full implementation is expected around 2028, following a 24-month transitional period from the date of entry into force.

For marketing authorisation holders (MAHs), manufacturers of generics and biosimilars, and distributors, the text changes the way in which product life cycles are planned. Here are the key points.

Data and market protection

  • regulatory data protection: this remains at eight years, during which the reference medicinal product’s dossier cannot be used to authorise a generic or biosimilar;
  • market protection: the basic duration is reduced from two years to one year and may be extended by one year subject to specific conditions (for example, an unmet medical need or certain comparative studies), with a further year for a new indication offering significant clinical benefit;
  • overall cap: eleven years of regulatory protection, rising to twelve where a transferable voucher for priority antimicrobials applies;
  • orphan medicines: exclusivity shifts from an indication-based approach to a product-based one, with a standard duration of nine years and eleven years for ‘breakthrough’ medicines.

These protections complement patents and supplementary protection certificates, which remain governed separately and must be assessed on a case-by-case basis.

Supply obligations and shortages

For those marketing medicinal products, this is the most significant aspect. Member States may require the marketing authorisation holder to ensure the availability of the product within their territory and, if continuous supply is not guaranteed within the prescribed time limits, regulatory market protection may cease to apply in that State. Provisions are also made for shortage prevention plans for prescription-only medicines and for faster notification of supply disruptions. In practice, availability on the national market becomes a condition for maintaining protection.

Bolar exemption

The Bolar exemption is being extended: generics and biosimilars will be able to carry out preparatory activities relating to pricing and reimbursement, health technology assessment and participation in public tenders in advance, provided that marketing only takes place after the expiry of the protection periods. The competitive advantage lies in being able to enter the market from the very first available day.

What to do now

The transitional period allows time to prepare, but it is best to start on certain steps straight away:

  1. map the products in your portfolio and assess the impact of the new protection periods on launch and protection strategies;
  2. review supply, distribution and licence agreements for clauses relating to procurement, production stoppages and liability;
  3. put in place internal procedures and information flows for notifications and shortage prevention plans;
  4. for generics and biosimilars, plan the preparatory activities permitted under the new Bolar exemption;
  5. monitor implementing measures and national transposition, which will affect practical application.

The firm supports pharmaceutical companies, distributors and investors in the sector with regulatory and contractual advice and in extraordinary transactions. For an analysis of your portfolio and contracts, please contact us via the Contact page; for the relevant sector, see Pharmaceuticals and Healthcare.

This text summarises the contents of the package based on public agreements and institutional sources; the definitive provisions and dates of application are those set out in the acts published in the Official Journal of the European Union. Sources: Council of the European Union, page on the pharmaceutical package; professional commentaries from March and April 2026.


Leave a Reply

Your email address will not be published. Required fields are marked *